

March 30, 2025

The Manager, Listing Department  
The National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
NSE Symbol: PANACEABIO

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
BSE Scrip Code: 531349

**Sub: Intimation of completion of tenure of Mrs. Manjula Upadhyay as an Independent Director**

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we would like to inform you that Mrs. Manjula Upadhyay (DIN: 07137968), Independent Director of the Company has completed her second and final term of 5 (five) consecutive years as Independent Director on March 29, 2025 and consequently she has ceased to be the director of the Company. Accordingly, she has also ceased to be the Chairperson / member of the Committees of the Board of Directors of the Company.

Mrs. Manjula Upadhyay will however continue to be non-executive independent director of the Company’s material wholly-owned subsidiary company, Panacea Biotec Pharma Limited.

The Board of Directors and the Management of the Company express deep appreciation and gratitude to the aforesaid director for her extensive contribution and guidance towards the business growth of the Company.

The details required to be disclosed under Regulation 30 of the SEBI LODR Regulations read along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed herewith as **Annexure - A**.

This is for your kind information and record please.

Thanking you,  
Sincerely yours,  
For **Panacea Biotec Limited**

**Vinod Goel**  
**Group CFO and Head Legal**  
**& Company Secretary**

**Annexure - A**

<b>S. No.</b>	<b>Particulars</b>	<b>Description</b>
1.	Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Mrs. Manjula Upadhyay has ceased to be Independent Director upon completion of her 2 <sup>nd</sup> and final tenure as an Independent Director of the Company
2.	Date of <del>appointment / re-appointment /</del> cessation (as applicable) & <del>term of appointment/re-appointment</del>	March 29, 2025
3.	Brief profile, in case of appointment	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable